20.500.12556/RUL-186859 Imunoterapevtski potencial bispecifičnih protiteles The immunotherapeutic potential of bispecific antibodies Namen diplomskega dela je bil predstaviti zgradbo, mehanizme delovanja, molekularne konstrukte, tarčne molekule ter klinično uporabo bispecifičnih protiteles (BsAbs) pri zdravljenju raka. Diplomsko delo temelji na pregledu sodobne znanstvene literature s področja imunoterapije, pri čemer so bili analizirani mehanizmi delovanja BsAbs, njihove terapevtske tarče, odobrena zdravila, klinična učinkovitost, možnosti kombiniranja z drugimi oblikami zdravljenja ter omejitve njihove uporabe. Pregled literature je pokazal, da BsAbs učinkovito preusmerjajo T-limfocite ali druge efektorske imunske celice proti tumorskim celicam ter predstavljajo eno najpomembnejših oblik sodobne protitumorske imunoterapije. Največji klinični uspeh doslej je bil dosežen pri zdravljenju hematoloških malignomov, medtem ko njihova uporaba pri solidnih tumorjih ostaja omejena zaradi heterogenosti tumorjev, imunosupresivnega tumorskega mikrookolja in razvoja odpornosti. Pomembne prednosti BsAbs so njihova modularna zasnova, možnost kombiniranja z drugimi terapevtskimi pristopi ter takojšnja dostopnost v primerjavi z nekaterimi celičnimi terapijami. Nadaljnji razvoj bo usmerjen v optimizacijo molekularne zasnove, identifikacijo napovednih biomarkerjev in razvoj večspecifičnih protiteles, kar bo omogočilo učinkovitejše, varnejše in bolj individualizirano zdravljenje bolnikov z rakom. The aim of this bachelor's thesis was to present the structure, mechanisms of action, molecular constructs, target molecules, and clinical applications of bispecific antibodies (BsAbs) in cancer treatment. The thesis is based on a review of current scientific literature in the field of cancer immunotherapy, focusing on the mechanisms of action of BsAbs, their therapeutic targets, approved drugs, clinical efficacy, combination strategies with other treatment modalities, and the limitations of their clinical use. The literature review demonstrated that BsAbs effectively redirect T cells and other effector immune cells toward tumor cells, making them one of the most promising approaches in modern cancer immunotherapy. The greatest clinical success has been achieved in the treatment of hematological malignancies, whereas their application in solid tumors remains limited due to tumor heterogeneity, the immunosuppressive tumor microenvironment, and the development of treatment resistance. Important advantages of BsAbs include their modular design, the possibility of combining them with other therapeutic approaches, and their immediate availability compared with certain cell based therapies. Future development will focus on optimizing antibody design, identifying predictive biomarkers, and developing multispecific antibodies to enable more effective, safer, and personalized cancer treatment. biotehnologija bispecifična protitelesa imunoterapija rak biotechnology bispecific antibodies immunotherapy cancer true false false Slovenski jezik Angleški jezik Diplomsko delo/naloga 2026-09-06 07:16:43 2026-09-06 07:16:48 2026-09-07 12:08:12 0000-00-00 00:00:00 2026 0 0 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 287129 290204675 61008.pdf 61008.pdf 1 E10E5C0C0EC1B5BD406CA244427995AC 8e789ba69a1d81cfe771ba27741f14f977941546f23a354dea862590e234b26b 278ef192-a9b2-11f1-8bc5-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=246238 Biotehniška fakulteta 0 0 0